RLYB Earnings Date: Mar 11, 2027 (Estimated) — Rallybio Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is RLYB's next earnings date?
Rallybio Corporation (RLYB) is expected to report Q4 2026 earnings on Thursday, March 11, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.60.
How did RLYB do in its last earnings report?
In its most recent report on Oct 27, 2026, Rallybio Corporation posted EPS of -$0.48 versus the -$1.44 estimate, a beat of 66.7%. The stock's 1-day post-earnings move was -4.0%.
How much does RLYB stock move after earnings?
RLYB beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.3% (up or down) in the day after earnings.
About Rallybio Corporation
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
🤖 AI Earnings Analysis
RLYB’s $0.48 loss per share beat estimates by $0.96, but remains a weak, loss-making biotech result; absent revenue or a disclosed catalyst, the unusually large surprise offers little evidence of improving fundamentals.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | -1.44 | -0.48 | +66.67% | — | ✅ Beat | -3.96% | — | — | |
| 2026-08-06 | Q2 2026 | -1.28 | -0.84 | +34.45% | $0 | ✅ Beat | +0.31% | +2.79% | +4.55% |
| 2026-05-13 | Q1 2026 | -1.20 | -1.46 | -21.67% | $212,000 | ❌ Miss | -0.98% | +1.60% | +10.94% |
| 2026-03-16 | Q4 2025 | -1.14 | -1.03 | +9.65% | $222,000 | ✅ Beat | -0.95% | -6.63% | -13.16% |
| 2025-11-06 | Q3 2025 | -0.22 | -0.14 | +36.36% | $212,000 | ✅ Beat | +2.16% | +11.68% | +5.84% |
| 2025-03-13 | Q4 2024 | -0.29 | -0.25 | +13.79% | $38,000 | ✅ Beat | -0.44% | +10.64% | -61.96% |
| 2024-11-07 | Q3 2024 | -0.37 | -0.26 | +29.73% | $299,000 | ✅ Beat | -1.00% | +9.00% | +6.00% |
| 2024-03-12 | Q4 2023 | -0.46 | -0.50 | -8.70% | $0 | ❌ Miss | -8.70% | -11.41% | -11.41% |
Showing last 8 quarters.